Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

These five Dividend Aristocrats have the least negligible impact from the tariffs and are ideal for passive income investors.

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

It has already been tested in five placebo-controlled mid-stage trials in psoriatic arthritis ... block are DMVT-502 for vitiligo and atopic dermatitis, DMVT-503 for acne and DMVT-504 for ...

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which ... in its approved indications of RA and psoriatic arthritis. Sales reached $1.77bn ...

Chronic workplace stress doesn’t just stay bottled up in your headspace. Instead, it manifests physically, particularly ...